← Leaderboards
Nigel A Calcutt
University Of California San Diego
$7,191,199
Attributed
$8,554,195
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,554,195 · 8
By mechanism
R01$4,780,247 · 3
R44$2,026,502 · 1
R21$1,047,955 · 3
R41$699,491 · 1
Top collaborators
- Graham Beaton2 shared
- Angela Hansen1 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Donald G. Guiney$13,029,168
- Cecilia Y Cheung$2,548,715
- Martin Marsala$11,581,323
- Vijayalakshmi S Pratha$232,740
- Mark S Wallace$2,021,221
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventRattusNeuropathyNeuronsDiabetes MellitusFda ApprovedDiabetic NeuropathiesSensoryPeripheralDiabetic PatientTranslatingIn VitroClinical TrialsIndexingPeripheral NervesAdultDiabeticAdverse EffectsClinical ResearchNovel Therapeutic InterventionPainHyperalgesiaNervePeripheral Nervous System Diseases
Grant awards (29)
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$990,691
R44 · FY2022 · DK
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$1,035,811
R44 · FY2021 · DK
Development of a topical fixed-dose combination drug for peripheral neuropathic pain.$699,491
R41 · FY2020 · NS
Cholinergic constraint and diabetic neuropathy$300,207
R01 · FY2017 · NS · contact PI
Cholinergic constraint and diabetic neuropathy$313,957
R01 · FY2016 · NS · contact PI
Muscarinic receptor antagonists as a therapy for diabetic neuropathy$17,894
R21 · FY2016 · DK · contact PI
Cholinergic constraint and diabetic neuropathy$314,388
R01 · FY2015 · NS · contact PI
Muscarinic receptor antagonists as a therapy for diabetic neuropathy$180,906
R21 · FY2015 · DK · contact PI
Cholinergic constraint and diabetic neuropathy$311,243
R01 · FY2014 · NS · contact PI
Muscarinic receptor antagonists as a therapy for diabetic neuropathy$229,519
R21 · FY2014 · DK · contact PI
Cholinergic constraint and diabetic neuropathy$328,138
R01 · FY2013 · NS · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$321,778
R01 · FY2011 · DK · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$325,029
R01 · FY2010 · DK · contact PI
Non Phamacologic Treatments for Diabetic Neuropathy$162,615
R21 · FY2010 · NS · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$30,000
R01 · FY2010 · DK · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$328,313
R01 · FY2009 · DK · contact PI
Non Phamacologic Treatments for Diabetic Neuropathy$157,413
R21 · FY2009 · NS · contact PI
Non Phamacologic Treatments for Diabetic Neuropathy$17,604
R21 · FY2009 · NS · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$322,290
R01 · FY2008 · DK · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$254,644
R01 · FY2006 · DK · contact PI
Near Infra Red Energy To Treat Diabetic Neuropathy$139,554
R21 · FY2006 · NS · contact PI
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$260,976
R01 · FY2005 · DK
Near Infra Red Energy To Treat Diabetic Neuropathy$142,450
R21 · FY2005 · NS
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$261,170
R01 · FY2004 · DK
Mechanisms of Spinally-Mediated Hyperalgesia in Diabetes$319,502
R01 · FY2003 · DK
PROSAPOSIN AND PROSAPTIDES IN DIABETIC NEUROPATHY$270,368
R01 · FY2002 · NS
PROSAPOSIN AND PROSAPTIDES IN DIABETIC NEUROPATHY$262,492
R01 · FY2001 · NS
PROSAPOSIN AND PROSAPTIDES IN DIABETIC NEUROPATHY$1,516
R01 · FY2001 · NS
PROSAPOSIN AND PROSAPTIDES IN DIABETIC NEUROPATHY$254,236
R01 · FY2000 · NS